Skip to main content

Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.

Publication ,  Journal Article
Willis, JR; Sapparapu, G; Murrell, S; Julien, J-P; Singh, V; King, HG; Xia, Y; Pickens, JA; LaBranche, CC; Slaughter, JC; Montefiori, DC ...
Published in: J Clin Invest
June 2015

Several HIV envelope-targeting (Env-targeting) antibodies with broad and potent neutralizing activity have been identified and shown to have unusual features. Of these, the PG9 antibody has a long heavy chain complementarity determining region 3 (HCDR3) and possesses unique structural elements that interact with protein and glycan features of the HIV Env glycoprotein. Here, we used the Rosetta software suite to design variants of the PG9 antibody HCDR3 loop with the goal of identifying variants with increased potency and breadth of neutralization for diverse HIV strains. One variant, designated PG9_N100(F)Y, possessed increased potency and was able to neutralize a diverse set of PG9-resistant HIV strains, including those lacking the Env N160 glycan, which is critical for PG9 binding. An atomic resolution structure of the PG9_N100(F)Y fragment antigen binding (Fab) confirmed that the mutated residue retains the paratope surface when compared with WT PG9. Differential scanning calorimetry experiments revealed that the mutation caused a modest increase in thermodynamic stability of the Fab, a feature predicted by the computational model. Our findings suggest that thermodynamic stabilization of the long HCDR3 in its active conformation is responsible for the increased potency of PG9_N100(F)Y, and strategies aimed at stabilizing this region in other HIV antibodies could become an important approach to in silico optimization of antibodies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

June 2015

Volume

125

Issue

6

Start / End Page

2523 / 2531

Location

United States

Related Subject Headings

  • Software
  • Protein Structure, Tertiary
  • Models, Molecular
  • Immunology
  • Humans
  • HIV-1
  • HIV Envelope Protein gp160
  • HIV Antibodies
  • Complementarity Determining Regions
  • 42 Health sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Willis, J. R., Sapparapu, G., Murrell, S., Julien, J.-P., Singh, V., King, H. G., … Crowe, J. E. (2015). Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest, 125(6), 2523–2531. https://doi.org/10.1172/JCI80693
Willis, Jordan R., Gopal Sapparapu, Sasha Murrell, Jean-Philippe Julien, Vidisha Singh, Hannah G. King, Yan Xia, et al. “Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.J Clin Invest 125, no. 6 (June 2015): 2523–31. https://doi.org/10.1172/JCI80693.
Willis JR, Sapparapu G, Murrell S, Julien J-P, Singh V, King HG, et al. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest. 2015 Jun;125(6):2523–31.
Willis, Jordan R., et al. “Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth.J Clin Invest, vol. 125, no. 6, June 2015, pp. 2523–31. Pubmed, doi:10.1172/JCI80693.
Willis JR, Sapparapu G, Murrell S, Julien J-P, Singh V, King HG, Xia Y, Pickens JA, LaBranche CC, Slaughter JC, Montefiori DC, Wilson IA, Meiler J, Crowe JE. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J Clin Invest. 2015 Jun;125(6):2523–2531.

Published In

J Clin Invest

DOI

EISSN

1558-8238

Publication Date

June 2015

Volume

125

Issue

6

Start / End Page

2523 / 2531

Location

United States

Related Subject Headings

  • Software
  • Protein Structure, Tertiary
  • Models, Molecular
  • Immunology
  • Humans
  • HIV-1
  • HIV Envelope Protein gp160
  • HIV Antibodies
  • Complementarity Determining Regions
  • 42 Health sciences